Literature DB >> 8172845

Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia.

M Guérin1, P J Dolphin, M J Chapman.   

Abstract

Elevated cholesteryl ester transfer protein-mediated transfer of cholesteryl ester (CE) from high-density lipoprotein (HDL) to low-density lipoprotein (LDL) may contribute to the atherogenicity of LDL in subjects with familial hypercholesterolemia (FH). To identify the major CE acceptors among LDL subspecies, we investigated the qualitative and quantitative features of CE transfer and exchange to LDL on incubation of plasma under physiological conditions. LDL subspecies were fractionated by density-gradient ultra-centrifugation. Both mass transfer and exchange of HDL CE to and with very-low-density lipoprotein plus intermediate-density lipoprotein and LDL were linear for the first 6 hours of incubation. Thereafter mass transfer ceased, but exchange continued at a comparable rate. The rate of CE mass transfer to apolipoprotein B-containing lipoproteins was significantly enhanced in heterozygous FH subjects compared with normolipidemic individuals (91.6 +/- 28.2 versus 52.9 +/- 19.6 micrograms CE/h per milliliter plasma, FH versus normal subjects, P < .02). In FH subjects the predominant LDL subspecies (LDL 3 and 4, d = 1.029 to 1.050 g/mL) accounted for 59.7 +/- 9.2% of the total CE transferred to LDL from HDL. By contrast, expression of CE mass transfer relative to the mass of each lipoprotein acceptor showed the triglyceride (TG)-rich (10.7% to 17.3%), light LDL subspecies (LDL 1 and 2, d = 1.019 to 1.029 g/mL) to represent the preferential CE acceptors (LDL 1 and 2, 94.8 to 136.5 micrograms CE/mg LDL mass; LDL 3 through 5 [d = 1.029 to 1.063 g/mL], 47.1 to 64.1 micrograms CE/mg LDL mass).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172845     DOI: 10.1161/01.atv.14.5.679

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  8 in total

1.  LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.

Authors:  Alexina Orsoni; Samir Saheb; Johannes H M Levels; Geesje Dallinga-Thie; Marielle Atassi; Randa Bittar; Paul Robillard; Eric Bruckert; Anatol Kontush; Alain Carrié; M John Chapman
Journal:  J Lipid Res       Date:  2011-09-26       Impact factor: 5.922

2.  Familial hypercholesterolemia associated with severe hypoalphalipoproteinemia in a Moroccan family.

Authors:  Karima Ait Chihab; Rachif Chater; Ana Cenarro; Anass Kettani; Sergio Castillo; Mohamed Loutfi; Josep Ribalta; Ahmed Adlouni; Miguel Pocovi; Mariame El Messal
Journal:  J Genet       Date:  2007-08       Impact factor: 1.166

Review 3.  Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia.

Authors:  Joan Carles Escolà-Gil; Noemí Rotllan; Josep Julve; Francisco Blanco-Vaca
Journal:  Curr Atheroscler Rep       Date:  2021-04-29       Impact factor: 5.113

Review 4.  Cholesteryl ester transfer protein and its inhibition.

Authors:  Olaf Weber; Hilmar Bischoff; Carsten Schmeck; Michael-Friedrich Böttcher
Journal:  Cell Mol Life Sci       Date:  2010-06-18       Impact factor: 9.261

5.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

6.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

7.  The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.

Authors:  J W A van der Hoorn; J W Jukema; L M Havekes; E Lundholm; G Camejo; P C N Rensen; H M G Princen
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

8.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.